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Overexpression of a rat kinase-deficient phosphoinositide 3-kinase, Vps34p,
inhibits cathepsin D maturation
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*Wellcome Trust Centre for the Study of Molecular Mechanisms in Disease, University of Cambridge, Addenbrookes Hospital, Hills Road, Cambridge CB2 2XY, U.K.,
and †Ludwig Institute for Cancer Research, University College London School of Medicine, Riding House Street, London W1P 8BT, U.K.
Lipid kinases and their phosphorylated products are important
regulators of many cellular processes, including intracellular
membrane traffic. The best example of this is provided by the
class III phosphoinositide 3-kinase (PI-3K), Vps34p, which is
required for correct targeting of newly synthesized carboxy-
peptidase Y to the yeast vacuole. A probable mammalian Vps34p
orthologue has been previously identified, but its function in the
trafficking of lysosomal enzymes has not been resolved. To
investigate the possible role(s) of mammalian Vps34p in protein
targeting to lysosomes, we have cloned the rat orthologue and
overexpressed a kinase-deficientmutant inHeLa cells. Expression
of the mutant protein inhibited both maturation of procathepsin
D and basal secretion of the precursor. In contrast wortmannin,
INTRODUCTION
There is now abundant evidence to indicate that, in addition to
their roles in cell signalling, lipid kinases and their phosphorylated
products are important regulators of intracellular membrane
traffic (reviewed in [1–3]). Perhaps the best example of this is
provided by the class III phosphoinositide 3-kinase (PI-3K),
Vps34p. This enzyme was first identified as a component of the
yeast vacuolar protein sorting machinery, which, when inacti-
vated, causes aberrant secretion of newly synthesized carboxy-
peptidase Y (CPY) from the yeast Golgi [4,5]. In addition to its
role in biosynthetic traffic, there is also considerable evidence to
support a requirement for Vps34p in the endocytic pathway. For
example, yeast expressing end12 (a mutant allele of VPS34) are
defective in transferring endocytosed α-factor to the vacuole [6],
and Vac1p!Vps19p, which is required for fusion of transport
vesicles to yeast endosomes, binds the lipid product of Vps34p
[7,8]. Vac1p is one member of a family of proteins that contain
the FYVE domain [3], which is implicated in PtdIns(3)P binding
[9,10]. Other yeast family members include Vps27p and the
PtdIns(3)P 5-kinase Fab1p. Deletion of FAB1 causes abnormally
large vacuoles containing fewer internal vesicles than normal to
form, suggesting that the lipid product is required for correct
sorting in the yeast multivesicular body [11]. Vps34p is the sole
PI-3K in Saccharomyces cere!isiae [5], which implies that this
enzyme has multiple roles throughout the yeast endocytic system.
In general, the membrane trafficking machinery appears highly
conserved between all eukaryotes. Hence the involvement of a
Vps34p orthologue in targeting newly synthesized lysosomal
hydrolases has been postulated on the basis that PI-3K inhibitors,
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TGN, trans-Golgi network.
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which also inhibited maturation, caused hypersecretion of the
precursor. We propose that mammalian Vps34p plays a direct
role in targeting lysosomal enzyme precursors to the endocytic
pathway in an analogous fashion to its role in the fusion of early
endocytic vesicles with endosomes. We further suggest that
inhibition of a wortmannin-sensitive enzyme, other than mam-
malianVps34p, is responsible for the failure to recycle unoccupied
mannose 6-phosphate receptors to the trans-Golgi network, and
consequent hypersecretion of lysosomal enzyme precursors
observed in the presence of this drug.
Key words: endosome, lysosome, phosphoinositide 3-kinase,
trans-Golgi network, wortmannin.
such as wortmannin and LY294002, cause aberrant secretion of
the precursor forms from cultured mammalian cells [12,13],
analogous to the mis-targeting of proCPY. Similarly, the ob-
servation that treatment of mammalian cells with wortmannin
andLY294002 drastically changed themorphology of endosomal
compartments [13–15] suggested that a mammalian orthologue
of Vps34p might be involved in trafficking to lysosomes, the
presumed mammalian equivalent of yeast vacuoles. However, in
contrast with yeast, mammalian cells contain multiple PI-3K
isoforms, many of which are sensitive to wortmannin and
LY294002 at the doses used to perturb membrane transport
[1,2], and so the involvement of an individual PI-3K isoform in
any particular cellular event cannot be determined on the basis
of inhibitor sensitivities alone.
A probable mammalian orthologue of Vps34p has been
identified [16], although to date its function has not been fully
determined. Experiments using antibodies towards the mam-
malian protein, which significantly reduced its enzymic activity,
caused defects in endosomal function in microinjected cells [17],
and inhibited an endosome–endosome fusion assay in !itro [18].
These effects were probably due to a failure of EEA1 (the
probable mammalian orthologue of Vac1p) to bind to endosomal
membranes. However, these studies did not address the in-
volvement of mammalian Vps34p in the biosynthetic pathway.
In the present study we report that overexpression of a dominant
negative form of rat Vps34p in HeLa cells does indeed inhibit the
trafficking of procathepsin D to lysosomes. In contrast with the
effects of the PI-3K inhibitor wortmannin, the mutant Vps34p
did not cause hypersecretion of the precursor protein. This
strongly suggests that multiple PI-3Ks are involved in trafficking
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of newly synthesized lysosomal hydrolases between the trans-
Golgi network (TGN) and lysosomes, and that a wortmannin-
sensitive enzyme other than mammalian Vps34p is responsible
for the hypersecretion which we and others have previously
observed.
MATERIALS AND METHODS
Cloning of rat VPS34
Rat liver cDNA (ClonTech, Cambridge, U.K.) was amplified by
PCR with degenerate oligonucleotides encoding the sense se-
quence GDDLRQD (5!-GGNGAYGAYYTNMGNCARGA-
3!) and the complement of FHADFG (5!-NCCRAARTCNG-
CRTGRAAN-3!). The 350–450 bp products were ligated into
pBluescript (Stratagene, Cambridge, U.K.) and inserts from 4
positive clones were sequenced. Two were 99% identical to the
catalytic domain of mouse p110α. Another had 58% identity to
VPS34. This insert was used to probe a rat insulinoma cDNA
expression library [19]. Three positive clones having identical
2.2 kb inserts were isolated and sequenced. Each contained a
2059 bp open reading frame, a stop codon and 3! untranslated
material. To obtain the 5! end, a PCR primer (5!-TTAGATG-
CAGGAGGAGGGGAGGCC-3!) complementary to a region
900 bp from the 5! end of the partial clones was used to probe a
‘Marathon-Ready’ rat liver cDNA library (ClonTech) by 5!
rapid amplification of cDNA ends. The resulting 1400 bp PCR
product comprised 50 bp of 5! untranslated sequence upstream
of a Kozak consensus sequence, an initial ATG codon and an
additional 598 bp 5! to the overlap with the previous clones. The
complete cDNA was then assembled using a unique NdeI
restriction site, and re-sequenced in both directions using the
service provided by the Department of Biochemistry, University
of Cambridge. The contiguous clone contained a 2661 bp open
reading frame encoding a predicted 887 residue protein (sub-
mitted to EMBL!GenBank" as AJ006710).
Mutagenesis
cDNA clones encoding mutations corresponding to Asp!"#"
Ala andAsn!"$" Ile were constructed as follows: PCR fragments
were generated using a primer containing the start codon, 5!-
TGTGCCGAGCTTGTCATGGGGGA-3!, and a mutagenic
primer, 5!-CTTTGTTAACAGAAGGATATCTAGATGCCG-
GGCTC-3!, containing both of the point mutations described
above, as well as two silent mutations which generated an XbaI
site to provide a diagnostic tool for isolating mutant clones
(mutations are shown in bold, an HpaI site is underlined). The
PCR fragment was isolated, purified and digested with HpaI
generating a 1241 bp fragment. The wild-type sequence was then
replaced by the mutated fragment following HpaI digestion of
the original cDNA. Sequencing of both strands confirmed the
presence of the intended mutations, and the absence of any
additional changes. For expression studies in mammalian cells, a
BamH1 fragment containing the entire coding sequence and
approximately 300 bp of the 3! untranslated region of the wild-
type and mutant rat VPS34 was cloned into BamH1-cut
pCDNA3-puro (a gift from J. Karttunen, University of
Cambridge).
Cells and antibodies
BHK-21 [20], Cos-7 [21] and HeLa [22] cells were obtained from
the European Collection of Cell Cultures (Porton Down,
Salisbury, Wilts., U.K.), and maintained as recommended by the
suppliers.
Polyclonal rabbit anti-(human cathepsin D) serum was
obtained fromDako (HighWycombe, Bucks.,U.K.). To generate
antisera towards rat Vps34p a KpnI–BamHI fragment com-
prising amino acids 789–887 (see Figure 1, top panel) was
fused in frame to glutathione S-transferase (pGEX; Pharmacia,
Milton Keynes, U.K.). The fusion protein was purified from
Escherichia coli lysates according to the methods recommended
by the manufacturers, and polyclonal antisera were raised in
guinea pigs.
Transfection of cell lines
For analysis of lipid kinase activity BHK-21 cells were transiently
transfected by lipofection (AMINE$ ; Gibco BRL,
Paisley, Renfrewshire, Scotland,U.K.) with the empty pCDNA3-
puro vector, or vector containing wild-type or mutant ratVPS34.
Following incubation for 24 h cells were harvested, and PI-3K
activity was assayed in guinea pig anti-(rat Vps34p) immuno-
precipitates essentially as described by Volinia et al. [16]. Ex-
pression of rat Vps34p in the transfected cells was monitored by
Western blotting [23], using a horseradish peroxidase-conjugated
rabbit anti-(guinea pig Ig) secondary antiserum (Sigma) and
enhanced chemiluminescence detection (Pierce & Warriner,
Chester, U.K.).
For analysis of rat Vps34p–p150 association, Cos-7 cells were
cotransfected by lipofection with pMT2-p150 [24] and either the
empty pCDNA3-puro vector, or vector containing wild-type or
mutant rat VPS34. After 24 h the culture medium was replaced
with methionine- and cysteine-free Dulbecco’s modified Eagle’s
medium (Sigma) containing 5% (v!v) dialysed newborn-calf
serum, and the cells were preincubated at 37 "C for 1 h. They
were then labelled in fresh methionine- and cysteine-free medium
supplemented with 83 µCi!ml ProMix (Amersham, Little
Chalfont, Bucks., U.K.) for an additional 2 h. After extensive
washing with ice-cold PBS the cells were solubilized as described
previously [12]. Vps34p and associated proteins were recovered
from the clarified lysates using the polyclonal guinea pig sera,
and were analysed by SDS!PAGE and fluorography [25].
For analysis of mammalian Vps34p function, HeLa cells were
transfected with either the empty pCDNA3-puro vector, or
vector containing mutant rat VPS34, using SuperFect (Qiagen,
Crawley, West Sussex, U.K.) according to the manufacturer’s
instructions. After 24 h the culture medium was supplemented
with 5 µg!ml puromycin (Sigma), and the surviving cells were
analysed 72 h post-transfection. Trafficking of (pro)cathepsin D
was assayed essentially as described previously [12], modified to
accommodate the use of adherent rather than suspension cells.
Briefly, the cells were washed twice with PBS, then incubated in
methionine-free alpha modification of minimal essential medium
Eagle (αMEM) (Sigma) containing 2.2 g!l sodium bicarbonate,
and 5% (v!v) dialysed newborn-calf serum, for 1 h at 37 "C in an
incubator with a CO
%
!air atmosphere (1:19). After washing
twice with PBS, methionine-free medium containing 20 mM
Hepes and 100 µCi!ml ProMix was added, and the cells were
incubated at 37 "C for 15 min. They were then transferred to ice,
washed three times with ice cold PBS!5 mg!ml BSA and chased
for up to 4 h in αMEM containing 20 mM Hepes, 1 mg!ml BSA
and 1 mM methionine. In some experiments the chase medium
also contained wortmannin (100 nM), which was replenished
every hour of the chase period. Labelled (pro)cathepsin D was
immunoprecipitated, and analysed by SDS!PAGE and Phospho-
Imaging (Fuji).
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For statistical analysis, the ratios of the amounts of the mature
product or secreted precursor recovered after a 4 h chase from
control and inhibited cells were calculated for each experiment,
and mean values were determined. The null hypothesis that there
was no difference between them (mean ratio# 1) was tested
using the Student’s t test.
RESULTS
The components involved in membrane trafficking pathways are
often highly conserved between yeast and higher eukaryotes. To
test the hypothesis that an enzyme related to the product of the
S. cere!isiae VPS34 gene is required for delivery of lysosomal
hydrolases to lysosomes, we used degenerate oligonucleotide
primers encoding conserved regions of the consensus lipid kinase
domain [26] to amplify cDNA from a rat liver library by PCR.
One product was 58% identical to yeast VPS34, and was used as
a probe to clone a probable rat orthologue. The predicted
protein sequence of rat Vps34p (Figure 1, top panel) was 36.7%,
50% and 93% identical to the S. cere!isiae [4], Drosophila
melanogaster [27], and human [16] orthologues respectively.
Comparative analysis of the predicted protein sequence of rat
Vps34p with those of a representative of the class I (p110β) or
class II (PI-3K-C2α) enzymes revealed four short regions showing
greater than 30% identity (Figure 1, bottom panel). Two of these
corresponded to the amino and carboxyl regions of the previously
defined lipid kinase domain, which, overall, showed greater than
40% identity. In contrast, comparison with S. cere!isiae Vps34p
revealed extensive similarity throughout the primary sequence.
The C-terminal third of the molecule was especially well
conserved, which may reflect the similar substrate specificities of
the two enzymes.
To confirm that the rat protein had enzymic activity we
introduced the cDNA into BHK-21 cells. As expected, Vps34p
immunoprecipitates from cells overexpressing the wild-type rat
Vps34p contained a high level of PI-3K activity (Figure 2), which
like yeast Vps34p [5] was specific for phosphoinositide as
substrate (results not shown).Unlike yeast Vps34p, but consistent
with the human enzyme, rat Vps34p was potently inhibited by
wortmannin [16,28]. To further examine the rat enzyme we
introduced two point mutations into the lipid kinase domain,
analogous to those previously shown to inhibit the activity of
yeast Vps34p [5]. As predicted, the mutant protein expressed in
BHK-21 cells was kinase inactive (Figure 2). These mutations
also abolished lipid kinase activity in human Vps34p (results not
shown).
In yeast, the introduction of mutations into Vps34p, which
abolish lipid kinase activity, creates a dominant-negative pheno-
type when kinase inactive protein is overproduced in a wild-type
strain. This occurs because the mutant protein competes with
wild-type Vps34p for binding to the myristoylated membrane
protein Vps15p, a protein kinase required for membrane
association and activation of the wild-type lipid kinase [29].
A Vps15p orthologue has been isolated in association with the
human enzyme [16,24], and so we postulated that kinase-deficient
Figure 1 cDNA and translated protein sequence of rat Vps34p
Top panel : rat cDNA was cloned and sequenced as described in the Materials and methods
section. The underlined region shows the original PCR product, and the amino acids in bold
are those mutated in the kinase-deficient constructs. Bottom panel : diagon analysis of the
predicted protein sequence of rat Vps34p with the sequences of human p110β [42], human
PI-3K-C2α [43], and S. cerevisiae Vps34p [4] was conducted using the Staden software
package [44]. The vertical lines within each plot show the boundaries of the PCR probe.
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Figure 2 PI-3K activity of wild-type and mutant rat Vps34p
PI-3K activity was determined in immunoprecipitates of BHK-21 cells transfected with pCDNA3
constructs encoding wild-type (columns 1, 4 and 5), mutant rat Vps34p (column 2) or vector
alone (column 3) as described in the Materials and methods section. Precipitations used guinea
pig anti-(rat Vps34p) (columns 1-4), or pre-immune sera (column 5). Analyses were conducted
in the absence (columns 1–3 and 5) or presence (column 4) of 100 nM wortmannin. Results
are expressed in arbitrary units following quantification using a Fuji Bas2000 PhosphoImager.
The inset shows an immunoblot of the expressed Vps34p from samples transfected with wild-
type (WT), mutant (M) or vector alone (V).
Figure 3 Co-precipitation of rat Vps34p and human p150
Cos-7 cells were transfected with cDNAs encoding wild-type (lanes 1, 3 and 5) or mutant (lane
4) rat Vps34p and human p150 (lanes 2–5) as described in the Materials and methods section.
The cells were radiolabelled 24 h post-transfection, and Vps34p and associated proteins were
recovered from detergent lysates using guinea-pig anti-(rat Vps34p) and Protein A. Lane 5
contains material recovered from the combined lysates of cells separately transfected with rat
Vps34p and human p150.
rat Vps34p would also act as a dominant-negative inhibitor if
expressed in mammalian cells. To confirm that the rat enzyme
could associate with the human Vps15p orthologue, we trans-
fected Cos-7 cells with cDNA encoding either wild-type or
mutant rat Vps34p with or without human Vps15p cDNA. As
shown in Figure 3, significant amounts of the overexpressed
human Vps15p could be recovered using antibodies towards rat
Vps34p in cells co-transfected with either the wild-type or mutant
lipid kinase (lanes 3 and 4). Interestingly the association
of Vps15p and Vps34p appeared to be dependent upon co-
expression within the same cells, since Vps15p was not efficiently
recovered if lysates from separately transfected cells were
combined prior to immunoprecipitation (lane 5).
We subsequently examined the effects of expressing the mutant
rat enzyme on cathepsin D targeting and maturation. Our
initial attempts to isolate stable lines expressing high levels of
Figure 4 Expression of kinase-deficient rat Vps34p in HeLa cells
(A) HeLa cells were transfected with vector alone (control) or vector containing mutant Vps34p
cDNA as described in the Materials and methods section. Radiolabelled (pro)cathepsin D was
recovered from cell detergent lysates and media respectively and analysed by SDS/PAGE and
PhosphoImaging. A representative experiment is shown. (B) The ratios of cathepsin D recovered
as the fully processed (mature) and secreted forms of cells, either transfected with mutant
Vps34p, or treated with 100 nM wortmannin, relative to the matched control cells, were
calculated. Columns 1 and 3 show the means$S.E.M. (n# 6) from experiments involving
cells transfected with mutant Vps34p (mut Vps34p), and columns 2 and 4 show the
means$range (n# 2) of wortmannin (WM) treated cells. The broken line shows the expected
ratio (1) if there were no difference between the inhibitor-treated cells and the control cells.
the mutant protein were unsuccessful, perhaps because of the
reported role of Vps34p in growth-factor stimulated mitogenesis
[17]. Accordingly we adopted a transient expression protocol,
and to overcome problems associated with untransfected cells,
utilized a vector conferring resistance to puromycin. This in-
hibitor killed more than 95% of HeLa cells not expressing the
pac gene product within 24 h of exposure (results not shown)
providing an efficient mechanism to discriminate between trans-
fected and untransfected cells. Indirect immunofluorescence
microscopy indicated that there was significant heterogeneity in
mutant Vps34p expression within the selected population of
cells, but that in all cases staining was essentially cytosolic
(results not shown).
In human cells procathepsin D is converted from the 53 kDa
precursor form, via a 47 kDa intermediate, into the mature
protein, which comprises two chains of 31 kDa and 14 kDa [30]
(Figure 4A). Maturation occurs following delivery of the pre-
cursor to late endocytic compartments, and is completed in
lysosomes [30]. Previously we showed that treatment of K562
cells with PI-3K inhibitors inhibited the maturation of pro-
cathepsin D [12], although we were uncertain whether this was
due to the inhibition of a Vps34p orthologue, or to inhibition of
another lipid kinase. Consistent with our previous observations,
treatment of HeLa cells with 100 nM wortmannin also inhibited
maturation of procathepsin D (Figure 4B, column 2). In
wortmannin-treated cells the inhibition of procathepsinDmatur-
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ation occurs because the protein is not targeted to the endocytic
pathway, but rather is secreted from the cell (Figure 4B, column
4). However although expression of the dominant-negative
mutantVps34p significantly inhibited procathepsinDmaturation
in the transfected cells (Figure 4B, column 1; P! 0.001), its
expression did not cause hypersecretion of the precursor, but in
fact reduced basal secretion to approximately 80% compared
with the control cells (Figure 4B, column 3; P! 0.025). A
similar effect on procathepsin D maturation was also observed in
Cos-7 cells expressing the mutant Vps34p (results not shown).
The effects of the mutant protein on lysosomal enzyme sorting
and maturation did not appear to be due to a general disturbance
of the early secretory pathway, since constitutive secretion of
cotransfected α
&
-antitrypsin was essentially identical in control
and mutant cells (results not shown). In addition, immuno-
fluorescence microscopy did not reveal any gross differences in
the respective subcellular distributions of (pro)cathepsin D,
cation-independent mannose 6-phosphate receptors, and the late
Golgi marker TGN46, between those cells expressing the mutant
Vps34p and those transfected with the empty vector (results not
shown).
DISCUSSION
Previously we, and others, have speculated that a mammalian
orthologue of yeast Vps34p might be required for delivery of
newly synthesized lysosomal hydrolases to lysosomes [12,13].
The data described in the present study provide the first direct
proof that this is indeed the case. However, in contrast with our
expectation that loss of Vps34p function would result in hyper-
secretion of lysosomal precursors, as is the case in wortmannin-
treated cells, we demonstrated that secretion was actually signifi-
cantly below basal levels in the presence of the dominant mutant.
This strongly suggests that at least one additional wortmannin-
sensitive enzyme is required for transport of newly synthesized
lysosomal enzymes from the TGN to lysosomes, and that,
functionally, this enzyme acts upstream of mammalian Vps34p.
Sorting of procathepsins at the TGN is a receptor-mediated
process involving the recognition of mannose 6-phosphate
residues [31]. Thus the hypersecretion observed in the presence of
PI-3K inhibitors indicates that under these conditions there are
insufficient unoccupied receptors in the TGN able to bind newly
synthesized precursor molecules. This could occur either if export
of receptor-ligand complexes from the TGN were blocked (with
the total pool of receptors accumulating in the TGN in an
occupied state), or alternatively if recycling of unoccupied
receptors to the TGN from endocytic compartments was in-
hibited. There is still much debate as to which interpretation is
correct, with some workers favouring a direct effect upon export
of receptor–ligand complexes from the TGN [13,32], and others
the perturbation of the recycling of the empty receptors back
to the TGN [14,15,33].
The data from the studies referred to above are interpreted
mainly in the context of the hypothesis that the PI-3K inhibitors
act predominantly at a single transport step. However, the results
of the present study support the alternative hypothesis that
multiple PI-3Ks are involved in trafficking of lysosomal pre-
cursors and their receptors. The export and recyclingmechanisms
of inhibition are not mutually exclusive. Thus the differences in
the conclusions of the various studies may reflect the relative
steady state distributions of mannose 6-phosphate receptors (and
consequent sensitivity to perturbation of either the export or
recycling pathway), or the absolute amounts of the various target
enzymes in the cell lines used. It is also interesting to note that the
recent study which investigated the effect of microinjecting
inhibitory antibodies against human Vps34p demonstrated
defects in the early endosomal pathway of human and rodent
cells [17], but did not show the large vacuoles often seen in
wortmannin-treated cells.
Our study showed that secretion of procathepsin D was not
stimulated by the presence of the mutant Vps34p, whereas it was
stimulated by the PI-3K inhibitor wortmannin. On this basis we
conclude that it is most likely that a wortmannin-sensitive
enzyme other than Vps34p is required for the recycling of
unoccupied mannose 6-phosphate receptors from endosomes to
the TGN, and that Vps34p has a regulatory function in the
forward pathway. Our hypothesis predicts that wortmannin
inhibits both the forward and recycling pathways, but that the
overall effect is that in the presence of the drug the pool of vacant
receptors in the TGN is depleted, but is not replenished, and
hence hypersecretion occurs. In contrast we suggest that ex-
pression of the mutant Vps34p imposes a kinetic block on
the movement of occupied receptors between the TGN and the
endocytic pathway, but does not prevent subsequent recycling of
the empty receptors, and that under these circumstances the pool
of free receptors in the TGN is not saturated. At present we
cannot be certain of the identity of the enzyme(s) whose inhibition
prevents the recycling of unoccupied receptors. Vps34p is the
only mammalian class III PI-3K identified [2]. Consequently,
assuming that there are no undiscovered class III enzymes, we
believe it is likely that either a class I or class II enzyme is the
relevant target. In this regard it should be noted that whereas PI-
3K-C2α is relatively insensitive to wortmannin, the β-isoform
has a similar sensitivity to that of mammalian Vps34p and the
class IA enzymes [2].
Our observation that expression of the mutant Vps34p inhibits
basal secretion of procathepsin D from HeLa cells suggests that
at least a proportion of ‘constitutive’ secretion is in fact receptor-
mediated, as has been proposed previously [34]. There are now
several lines of evidence to support the hypothesis that entry of
mannose 6-phosphate receptor–procathepsin complexes into the
endocytic pathway is at the level of early endosomes (for example
see [35,36]). Thus secretion could occur either through dis-
sociation of receptor–ligand complexes in early endosomes, and
entry of procathepsin D into the recycling pathway, or through
delivery of cation-dependent mannose 6-phosphate receptor–
procathepsin D complexes to the plasma membrane (perhaps via
early endosomes) and subsequent dissociation. In this regard it
should be noted that the cation-dependent mannose 6-phosphate
receptor, which is the major form expressed by HeLa cells [37],
does not bind extracellular ligand [31]. Nevertheless, whichever
the route of secreted procathepsin D, delivery of ligand–receptor
complexes to early endosomes raises the possibility that mam-
malian Vps34p is required for fusion of TGN-derived vesicles, in
a similar fashion to its role in the fusion of plasma membrane-
derived vesicles, with endosomes [18]. This hypothesis thus
predicts that a common mechanism underlies fusion of all
vesicles, whether derived from the biosynthetic or endocytic
pathway, with early endosomes.
Although we favour a direct role for the lipid product of
Vps34p in the fusion of TGN-derived, as well as endocytic,
transport vesicles with early endosomes, we cannot exclude the
alternative possibility that the enzyme is solely involved in
the fusion of endocytic vesicles, and that expression of the mutant
enzyme inhibits the biosynthetic pathway to lysosomes indirectly
by disrupting the target membranes of biosynthetic vesicles. The
results of the present study also do not exclude the possibility
that Vps34p is directly involved in the formation of transport
vesicles at the TGN, as was originally proposed for yeast Vps34p
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[5]. In this regard it should be noted that we were unable to detect
any overt redistribution of (pro)cathepsin D immunoreactivity
towards a more ‘Golgi-like ’ pattern in the cells expressing the
mutant Vps34p. Such a redistribution might have been expected
if the mutant protein was indeed inhibiting export from the
TGN. However, if, as we believe likely, the mutant protein is
imposing a kinetic rather than an absolute block upon transport,
we cannot be certain that the inhibition we observe in pulse–chase
experiments would necessarily be reflected in a significant change
to the steady-state distribution of the marker protein. None-
theless, there now appear to be better candidates than Vps34p for
the role of regulating the formation of transport vesicles at the
TGN. Thus two groups have each independently identified
distinct TGN-associated PI-3Ks, which differ from mammalian
Vps34p in either molecular size and!or wortmannin sensitivity
respectively [38,39]. Moreover PI-3K-C2α has now been identi-
fied as a component of TGN-derived clathrin-coated vesicles
[40,41].
In conclusion the present study directly demonstrates a role
for mammalian Vps34p in the transport of lysosomal enzyme
precursors to lysosomes, but also suggests the involvement of
other wortmannin-sensitive enzymes in this process. In yeast
Vps34p is the sole PI-3K [5], and appears to be involved in
multiple trafficking steps. In contrast it appears that in mam-
malian cells distinct enzymes have evolved to perform these
multiple tasks which are either all performed by Vps34p, or are
not required, in yeast.
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